Monday, 15 February 2016

MS SMART Still Recruiting

MS-SMART (Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial)
February 2016

Hi there!

Following Dr Chataway’s previous post on this blog, we wanted to inform you that recruitment is still ongoing for the MS-SMART trial and will end April 2016.

MS-SMART is a phase 2 clinical trial looking at disease progression in people with secondary progressive MS (SPMS). The study involves testing one of three different drugs (amiloride, riluzole and fluoxetine) against a placebo (dummy drug) to see if they can slow down the worsening of disability. As you are aware, this trial is important as there is currently no treatment for progression in MS.

You can read more about MS-SMART on our website:

or the MS Society website (CLICK HERE):

The trial inclusion criteria include:
-Diagnosis of SPMS
-Steady progression of clinical disability in the preceding 2 years
-Still able to walk at least 20 metres with bilateral support (EDSS: 4.0-6.5)
-Aged 25 to 65 (inclusive)
-Able to undertake MRI
-Not on certain medications including: MS disease modifying therapy, fluoxetine, citalopram, escitalopram, and sertraline

So far, at all of the UK MS SMART recruiting sites, we have almost reached our participant target, and are getting in touch to see if anyone would be happy to attend our centre where we can offer you an appointment soon to check whether you might be eligible. We are based at the main MS-SMART site at UCL, Institute of Neurology, Queen Square, London.

Working together we can meet our target. If you are interested in taking part, please contact us via:

Or call: 07572898453

Thank you in advance,
Dr Domenico Plantone

On behalf of Dr Jeremy Chataway and the MS SMART team 


  1. Out of interest MSers who already currently take fluoxetine (Prozac) for depression, have they reported anything about their disease progression?

    1. Has there been any reply to this question, please?

    2. Has there been any reply to this question, please?


Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.